A randomized controlled, single blind clinical trial for safety and efficacy of grassroots leads in the management of Osteopenia / Osteoporosis among postmenopausal women

ational innovation foundation0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. B.M.D. T. score above -1 and less than -3.5
•2. All women who are consuming any drug which is known to affect bone metabolism in doses for e.g. SERMs, bisphophonates, calcitonin, Vit. D more than 60,000 units and corticosteroids more than 5mg/day for more than 3 months, methotrexate, anticonvulsants and diuretics.
•3. Patients suffering from congenital disorders (Dysosteogenesis and Marfan.s Syndrome)
•4. Patients with endocrine disorders (Hyperthyroidism, hyperparathyroidism, Untreated Cushing.s syndrome)
•5. Patients with evidence of malignancy
•6. Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Epilepsy)
•7. Patients suffering from chronic hepatic disorder, renal failure or cardiac dysfunction.
•8. Patient suffering from uncontrolled DM-2 or uncontrolled hypertension.
•8. Patients suffering from Osteomalacia.
•9. Patients suffering from Malabsorption syndrome
•10. Patients undergone Organ transplantation or on immunosuppressive therapy
•11. Prolonged immobilization
•12. Patients whose Serum Ca++ level < 2.2 or > 2.6 mmol/L ( < 9 or >10.5 mg/dL)
•13. History of renal stones
•14. Long bone fracture in last 6 months.
•15. Patient not ready to give an informed consent
•16. Subjects who has participated in any other clinical study in last 30 days.
•17. Patients with clinical evidence of active and chronic illness as rheumatoid arthritis, gout,SLE, Psoriatic arthritis.

发起方

ational innovation foundation